Quanta Dialysis Appoints President of North America Region

Quanta Dialysis Technologies Ltd., a British medical technology company developing dialysis products and services, has appointed John S. Lipman as president of North America.
 
Lipman will lead Quanta’s commercial operations and activities in the United States. He is already working to set up operations and to prepare for commercial launch, which is planned to follow soon after 510(k) clearance is obtained from the U.S. Food and Drug Administration for the company’s portable haemodialysis system SC+. He is also joined by Deborah Singer and Michelle Gazella as head of Chronic Sales and head of Clinical Support, respectively, bringing more than 40 years’ sales and clinical dialysis experience, with both holding senior positions at Fresenius Medical Care and NxStage.

John E Milad, CEO of Quanta, said: “I’m delighted that John has joined Quanta’s executive team. He brings a wealth of experience in launching novel medical products and building successful commercial organisations. I look forward to working with him to establish our US operations and bring SC+ to the world’s largest dialysis market.” 
 
Lipman has more than 25 years of leadership experience, developing and leading pre-launch and commercial companies across the medical device industry. He began working with Quanta as a consultant, and before that was chief commercial officer at NightBalance for four years prior to its acquisition by Philips, where he was responsible for leading the U.S. launch of the Lunoa sleep therapy device. At ApniCure Lipman was vice president of Marketing and Sales for eight years, where he deployed and expanded a U.S. sales team to launch a new treatment for obstructive sleep apnea. Lipman has also held positions at FoxHollow Technologies and two Johnson & Johnson subsidiaries, LifeScan and Scios.

Lipman graduated from California Polytechnical State University and earned an MBA in marketing from the University of San Francisco.
 
Lipman said: “I’m excited to be leading Quanta’s U.S. business development and commercial activity at such an important time in the company’s development. SC+ represents a unique and disruptive opportunity for the U.S. haemodialysis market, which rarely sees any innovation. In an industry which is notoriously slow to adapt and bring benefits from new technology to patients, Quanta is offering a versatile solution, designed with flexibility and freedom in mind that could revolutionise the way we think about kidney care. I look forward to leading Quanta’s U.S. commercial operations and working together with the senior leadership team to bring SC+ to as many patients and healthcare professionals as we can.”